FDA Accepts Supplement for BONSITY (Teriparatide) by Alvogen
The FDA has accepted the supplemental NDA for BONSITY, a teriparatide product from Alvogen.
Asset / Drug
Drug and asset intelligence for Alvogen with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.